Total Payments
$429,711
2024 Payments
$64,910
Companies
24
Transactions
460
Medicare Patients
11,374
Medicare Billing
$725,104
Payment Breakdown by Category
Other$242,033 (56.3%)
Consulting$78,979 (18.4%)
Research$57,649 (13.4%)
Travel$41,803 (9.7%)
Food & Beverage$9,179 (2.1%)
Education$68.50 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $170,354 | 76 | 39.6% |
| Consulting Fee | $78,979 | 30 | 18.4% |
| Unspecified | $57,649 | 3 | 13.4% |
| Travel and Lodging | $41,803 | 82 | 9.7% |
| Honoraria | $39,804 | 18 | 9.3% |
| Compensation for serving as faculty or as a speaker for a medical education program | $31,875 | 13 | 7.4% |
| Food and Beverage | $9,179 | 237 | 2.1% |
| Education | $68.50 | 1 | 0.0% |
Payments by Type
General
$372,062
457 transactions
Research
$57,649
3 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Eisai Inc. | $206,738 | 194 | $0 (2024) |
| Quidel Corporation | $71,824 | 6 | $0 (2023) |
| Horizon Therapeutics plc | $41,539 | 59 | $0 (2023) |
| ABBVIE INC. | $39,903 | 57 | $0 (2024) |
| GENZYME CORPORATION | $26,934 | 18 | $0 (2017) |
| Ortho-Clinical Diagnostics, Inc. | $16,573 | 5 | $0 (2024) |
| Amgen Inc. | $8,718 | 27 | $0 (2024) |
| Eli Lilly and Company | $7,388 | 3 | $0 (2020) |
| F. Hoffmann-La Roche AG | $3,458 | 1 | $0 (2022) |
| Horizon Pharma plc | $1,936 | 3 | $0 (2018) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $64,910 | 53 | Eisai Inc. ($38,796) |
| 2023 | $53,161 | 45 | Eisai Inc. ($38,048) |
| 2022 | $32,694 | 47 | EISAI INC. ($12,180) |
| 2021 | $21,167 | 37 | Eisai Inc. ($8,685) |
| 2020 | $76,666 | 61 | Quidel Corporation ($33,678) |
| 2019 | $88,897 | 95 | EISAI INC. ($53,982) |
| 2018 | $53,937 | 77 | Eisai Inc. ($37,326) |
| 2017 | $38,280 | 45 | GENZYME CORPORATION ($26,934) |
All Payment Transactions
460 individual payment records from CMS Open Payments — Page 1 of 19
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/18/2024 | Ascendis Pharma Inc | Yorvipath (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,106.00 | General |
| Category: Endocrinology | ||||||
| 12/10/2024 | ABBVIE INC. | SYNTHROID (Drug) | Food and Beverage | In-kind items and services | $18.87 | General |
| Category: IMMUNOLOGY | ||||||
| 12/03/2024 | Eisai Inc. | Lenvima (Drug) | Food and Beverage | In-kind items and services | $24.67 | General |
| Category: Oncology | ||||||
| 10/24/2024 | Eisai Inc. | Lenvima (Drug) | Compensation for serving as faculty or as a speaker for a medical education program | Cash or cash equivalent | $1,250.00 | General |
| Category: Oncology | ||||||
| 10/09/2024 | Ortho-Clinical Diagnostics, Inc. | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $6,000.00 | General |
| 10/09/2024 | Ortho-Clinical Diagnostics, Inc. | — | Travel and Lodging | Cash or cash equivalent | $791.00 | General |
| 10/09/2024 | Ortho-Clinical Diagnostics, Inc. | — | Travel and Lodging | Cash or cash equivalent | $734.80 | General |
| 10/09/2024 | Ortho-Clinical Diagnostics, Inc. | — | Food and Beverage | Cash or cash equivalent | $67.65 | General |
| 10/03/2024 | Eisai Inc. | Lenvima (Drug) | Compensation for serving as faculty or as a speaker for a medical education program | Cash or cash equivalent | $1,875.00 | General |
| Category: Oncology | ||||||
| 10/03/2024 | Eisai Inc. | Lenvima (Drug) | Compensation for serving as faculty or as a speaker for a medical education program | Cash or cash equivalent | $1,562.50 | General |
| Category: Oncology | ||||||
| 10/03/2024 | Eisai Inc. | Lenvima (Drug) | Food and Beverage | Cash or cash equivalent | $122.06 | General |
| Category: Oncology | ||||||
| 09/24/2024 | ABBVIE INC. | SYNTHROID (Drug) | Food and Beverage | In-kind items and services | $24.30 | General |
| Category: IMMUNOLOGY | ||||||
| 08/24/2024 | Amgen Inc. | TEPEZZA (Biological) | Consulting Fee | Cash or cash equivalent | $2,352.00 | General |
| Category: Inflammation/Rare Disease | ||||||
| 08/06/2024 | Lilly USA, LLC | RETEVMO (Drug) | Food and Beverage | In-kind items and services | $19.29 | General |
| Category: Oncology | ||||||
| 07/24/2024 | Ortho-Clinical Diagnostics, Inc. | — | Travel and Lodging | Cash or cash equivalent | $8,979.80 | General |
| 06/19/2024 | ABBVIE INC. | UBRELVY (Drug), SYNTHROID | Food and Beverage | In-kind items and services | $22.37 | General |
| Category: NEUROSCIENCE | ||||||
| 06/11/2024 | Amneal Pharmaceuticals LLC | UNITHROID (Drug) | Food and Beverage | In-kind items and services | $20.05 | General |
| Category: ENDOCRINOLOGY | ||||||
| 05/23/2024 | Eisai Inc. | Lenvima (Drug) | Consulting Fee | Cash or cash equivalent | $4,687.50 | General |
| Category: Oncology | ||||||
| 05/23/2024 | Eisai Inc. | Lenvima (Drug) | Travel and Lodging | Cash or cash equivalent | $625.00 | General |
| Category: Oncology | ||||||
| 05/22/2024 | Eisai Inc. | Lenvima (Drug) | Compensation for serving as faculty or as a speaker for a medical education program | Cash or cash equivalent | $3,750.00 | General |
| Category: Oncology | ||||||
| 05/22/2024 | Eisai Inc. | Lenvima (Drug) | Compensation for serving as faculty or as a speaker for a medical education program | Cash or cash equivalent | $1,562.50 | General |
| Category: Oncology | ||||||
| 05/22/2024 | Eisai Inc. | Lenvima (Drug) | Food and Beverage | Cash or cash equivalent | $19.64 | General |
| Category: Oncology | ||||||
| 05/21/2024 | Eisai Inc. | Lenvima (Drug) | Compensation for serving as faculty or as a speaker for a medical education program | Cash or cash equivalent | $5,000.00 | General |
| Category: Oncology | ||||||
| 05/21/2024 | Eisai Inc. | Lenvima (Drug) | Compensation for serving as faculty or as a speaker for a medical education program | Cash or cash equivalent | $1,562.50 | General |
| Category: Oncology | ||||||
| 05/21/2024 | Eisai Inc. | Lenvima (Drug) | Travel and Lodging | Cash or cash equivalent | $234.00 | General |
| Category: Oncology | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| Thyretain Cell Improvement TSI | Quidel Corporation | $33,678 | 1 |
| Post product comparison TSH-R-AB Immunoassays | Quidel Corporation | $20,513 | 1 |
| CIM RD005629 | F. Hoffmann-La Roche AG | $3,458 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 17 | 2,798 | 3,105 | $427,411 | $184,264 |
| 2022 | 21 | 3,244 | 6,807 | $456,106 | $230,536 |
| 2021 | 18 | 2,685 | 3,131 | $311,151 | $161,558 |
| 2020 | 17 | 2,647 | 3,152 | $213,489 | $148,746 |
Total Patients
11,374
Total Services
16,195
Medicare Billing
$725,104
Procedure Codes
73
All Medicare Procedures & Services
73 procedure records from CMS Medicare Utilization — Page 1 of 3
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 547 | 705 | $144,705 | $62,858 | 43.4% |
| 76536 | Ultrasound scan of head and neck soft tissue | Office | 2023 | 714 | 751 | $128,221 | $59,277 | 46.2% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 392 | 435 | $63,065 | $25,906 | 41.1% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 53 | 65 | $18,385 | $8,706 | 47.4% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 63 | 63 | $21,372 | $7,017 | 32.8% |
| 10005 | Fine needle aspiration biopsy using ultrasound guidance, first growth | Office | 2023 | 33 | 36 | $8,905 | $3,658 | 41.1% |
| 84443 | Blood test, thyroid stimulating hormone (tsh) | Office | 2023 | 201 | 210 | $6,510 | $3,457 | 53.1% |
| 99442 | Telephone medical discussion with physician, 11-20 minutes | Office | 2023 | 55 | 62 | $9,590 | $3,122 | 32.6% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2023 | 248 | 270 | $5,397 | $2,268 | 42.0% |
| 84481 | Thyroid hormone, t3 measurement, free | Office | 2023 | 111 | 113 | $4,859 | $1,876 | 38.6% |
| 84439 | Thyroxine (thyroid chemical), free | Office | 2023 | 201 | 210 | $6,510 | $1,856 | 28.5% |
| 88172 | Evaluation of fine needle aspirate | Office | 2023 | 32 | 37 | $4,417 | $1,577 | 35.7% |
| 84480 | Thyroid hormone, t3 measurement, total | Office | 2023 | 82 | 82 | $2,624 | $1,140 | 43.4% |
| 82306 | Vitamin d-3 level | Office | 2023 | 18 | 18 | $882.00 | $522.18 | 59.2% |
| 83970 | Parathormone (parathyroid hormone) level | Office | 2023 | 11 | 11 | $649.00 | $444.95 | 68.6% |
| 86800 | Thyroglobulin (thyroid protein) antibody measurement | Office | 2023 | 20 | 20 | $640.00 | $311.80 | 48.7% |
| 84432 | Thyroglobulin (thyroid related hormone) level | Office | 2023 | 17 | 17 | $680.00 | $267.58 | 39.4% |
| 76536 | Ultrasound scan of head and neck soft tissue | Office | 2022 | 666 | 702 | $105,624 | $56,085 | 53.1% |
| J0897 | Injection, denosumab, 1 mg | Office | 2022 | 49 | 3,060 | $100,980 | $53,848 | 53.3% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 421 | 498 | $74,769 | $45,707 | 61.1% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 485 | 531 | $66,375 | $31,560 | 47.5% |
| 99442 | Telephone medical discussion with physician, 11-20 minutes | Office | 2022 | 89 | 117 | $17,525 | $7,846 | 44.8% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 57 | 57 | $18,594 | $6,632 | 35.7% |
| 84443 | Blood test, thyroid stimulating hormone (tsh) | Office | 2022 | 296 | 391 | $12,121 | $6,489 | 53.5% |
| 84439 | Thyroxine (thyroid chemical), free | Office | 2022 | 280 | 372 | $11,532 | $3,315 | 28.7% |
About Dr. Mark Lupo, MD
Dr. Mark Lupo, MD is a Endocrinology, Diabetes & Metabolism healthcare provider based in Sarasota, Florida. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 04/27/2006. The National Provider Identifier (NPI) number assigned to this provider is 1528025319.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Mark Lupo, MD has received a total of $429,711 in payments from pharmaceutical and medical device companies, with $64,910 received in 2024. These payments were reported across 460 transactions from 24 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($170,354).
As a Medicare-enrolled provider, Lupo has provided services to 11,374 Medicare beneficiaries, totaling 16,195 services with total Medicare billing of $725,104. Data is available for 4 years (2020–2023), covering 73 distinct procedure/service records.
Ad
Practice Information
- Specialty Endocrinology, Diabetes & Metabolism
- Other Specialties Diabetes & Metabolism
- Location Sarasota, FL
- Active Since 04/27/2006
- Last Updated 11/28/2012
- Taxonomy Code 207RE0101X
- Entity Type Individual
- NPI Number 1528025319
Products in Payments
- Lenvima (Drug) $206,702
- Sofia2 (Device) $33,678
- TEPEZZA (Drug) $32,300
- CAPRELSA (Drug) $20,311
- Synthroid (Drug) $18,575
- SYNTHROID (Drug) $16,053
- TEPEZZA (Biological) $8,224
- THYROID CANCER (Drug) $6,610
- TEPRO (Drug) $1,936
- Vitrakvi (Drug) $1,656
- Yorvipath (Drug) $1,106
- NATPARA (Drug) $502.77
- EVENITY (Biological) $297.56
- Tirosint (Drug) $288.98
- RETEVMO (Drug) $260.80
- UNITHROID (Drug) $238.59
- Prolia (Biological) $196.57
- Tymlos (Biological) $93.50
- LICART (Drug) $78.36
- FORTEO (Drug) $51.34
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Endocrinology, Diabetes & Metabolism Doctors in Sarasota
Jesus Perez, Md, MD
Endocrinology, Diabetes & Metabolism — Payments: $343,841
Endocrinology, Diabetes & Metabolism $343,841
Dr. Raymond De La Rosa, M.d, M.D
Endocrinology, Diabetes & Metabolism — Payments: $123,034
Endocrinology, Diabetes & Metabolism $123,034
Sonia Sharma, Md, MD
Endocrinology, Diabetes & Metabolism — Payments: $6,106
Endocrinology, Diabetes & Metabolism $6,106
Motaz Agabani, Md, MD
Endocrinology, Diabetes & Metabolism — Payments: $5,776
Endocrinology, Diabetes & Metabolism $5,776
Angela Boldo, M.d, M.D
Endocrinology, Diabetes & Metabolism — Payments: $4,101
Endocrinology, Diabetes & Metabolism $4,101
Dr. Jose Antunes, M.d, M.D
Endocrinology, Diabetes & Metabolism — Payments: $3,974
Endocrinology, Diabetes & Metabolism $3,974